74 related articles for article (PubMed ID: 17072716)
21. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.
Kondo K; Yamasaki S; Inoue N; Sugie T; Teratani N; Kan T; Shimada Y
Surg Today; 2006; 36(11):966-74. PubMed ID: 17072716
[TBL] [Abstract][Full Text] [Related]
22. HIF-1α siRNA and cisplatin in combination suppress tumor growth in a nude mice model of esophageal squamous cell carcinoma.
Liao HY; Wang GP; Gu LJ; Huang SH; Chen XL; Li Y; Cai SW
Asian Pac J Cancer Prev; 2012; 13(2):473-7. PubMed ID: 22524809
[TBL] [Abstract][Full Text] [Related]
23. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
24. p-Hydroxylcinnamaldehyde from cochinchinamomordica seed reverses resistance to TRAIL in human oesophageal squamous cell carcinoma via the activation of the p38 mitogen-activated protein kinase signalling pathway.
Ma M; Zhang C; Xiang XH; Deng XQ; Dai SL; Wei SS; Zhang XM; Zhao LM; Liu YJ; Shan BE
Biomed Pharmacother; 2020 Jan; 121():109611. PubMed ID: 31731196
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y
Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725
[TBL] [Abstract][Full Text] [Related]
27. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection.
Inoue N; Yamasaki S; Kondo K; Kan T; Furumoto K; Imamura M
Surg Today; 2003; 33(4):269-76. PubMed ID: 12707821
[TBL] [Abstract][Full Text] [Related]
29. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
[TBL] [Abstract][Full Text] [Related]
30. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.
Kim JY; Kim YH; Chang I; Kim S; Pak YK; Oh BH; Yagita H; Jung YK; Oh YJ; Lee MS
Oncogene; 2002 May; 21(20):3139-48. PubMed ID: 12082629
[TBL] [Abstract][Full Text] [Related]
31. Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells.
Sarker M; Ruiz-Ruiz C; Robledo G; López-Rivas A
Oncogene; 2002 Jun; 21(27):4323-7. PubMed ID: 12082620
[TBL] [Abstract][Full Text] [Related]
32. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
Ravi R; Bedi A
Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
[TBL] [Abstract][Full Text] [Related]
33. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
Suliman A; Lam A; Datta R; Srivastava RK
Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196
[TBL] [Abstract][Full Text] [Related]
34. Avoiding premature apoptosis of normal epidermal cells.
Qin J; Chaturvedi V; Bonish B; Nickoloff BJ
Nat Med; 2001 Apr; 7(4):385-6. PubMed ID: 11283637
[No Abstract] [Full Text] [Related]
35. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.
Lawrence D; Shahrokh Z; Marsters S; Achilles K; Shih D; Mounho B; Hillan K; Totpal K; DeForge L; Schow P; Hooley J; Sherwood S; Pai R; Leung S; Khan L; Gliniak B; Bussiere J; Smith CA; Strom SS; Kelley S; Fox JA; Thomas D; Ashkenazi A
Nat Med; 2001 Apr; 7(4):383-5. PubMed ID: 11283636
[No Abstract] [Full Text] [Related]
36. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.
Eggert A; Grotzer MA; Zuzak TJ; Wiewrodt BR; Ho R; Ikegaki N; Brodeur GM
Cancer Res; 2001 Feb; 61(4):1314-9. PubMed ID: 11245427
[TBL] [Abstract][Full Text] [Related]
37. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Hopkins-Donaldson S; Bodmer JL; Bourloud KB; Brognara CB; Tschopp J; Gross N
Cancer Res; 2000 Aug; 60(16):4315-9. PubMed ID: 10969767
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.
Jo M; Kim TH; Seol DW; Esplen JE; Dorko K; Billiar TR; Strom SC
Nat Med; 2000 May; 6(5):564-7. PubMed ID: 10802713
[TBL] [Abstract][Full Text] [Related]
39. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
